Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Avoid Covaxin in case of allergies, fever: Bharat Biotech

IANS
Updated: January 19th, 2021, 13:40 IST
in Home News, National
0
Covaxin

Photo courtesy: pharmaceutical-technology.com

Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Hyderabad: Bharat Biotech, makers of India’s first indigenous vaccine for Covid-19, has advised people not to take ‘Covaxin’ if they have allergies, fever, bleeding disorder, are on blood thinners, immune-compromised, or are on medicines that affect immune system.

The Hyderabad-based vaccine-maker, in a fact sheet for recipients and caregivers, said that even pregnant and nursing women should not take the vaccine.

Also Read

PM Modi holds talks with Argentine President Milei

PM Modi holds talks with Argentine President Milei

6 hours ago
Newlywed couple found hanging from same rope in bedroom; police say...

Newlywed couple found hanging from same rope in bedroom; police say…

9 hours ago

People who have taken another Covid-19 vaccine or are suffering from any other serious health-related issues should also not take Covaxin.

Bharat Biotech reiterated that the Drugs Controller General of India (DCGI) had authorised the “restricted use of Covaxin under clinical trial mode”.

“Individuals who are prioritised under the public health programme of the Health Ministry will be covered under this endeavour. Informing the individuals about the offer to vaccinate them with Covaxin will rest with the respective government programme officials. Those offered Covaxin at pre-specified booths will have the option to receive or reject the administration of the vaccine,” says the fact sheet that surfaced on Tuesday.

Company sources told IANS that the fact sheet was issued last week.

“As with any new medicine, this vaccine will be closely monitored to allow quick identification of any new safety information,” said Bharat Biotech. Side effects can be reported to toll-free number 18001022245.

The vaccine-maker said that in phase 1 and 2 clinical trials, Covaxin has demonstrated the ability to produce antibodies against Covid-19. However, the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase 3 clinical trial.

In phase 1 and 2 trials, 680 people were administered two doses each of Covaxin. The phase 3 clinical trial with 25,800 participants is on. The first dose was administered to them on January 6.

In the ongoing clinical trial, Covaxin has shown to generate immunity following two doses given four weeks apart, the firm said.

Covaxin, which Bharat Biotech developed in collaboration with the Indian Council of Medical Research and National Institute of Virology, and ‘Covishield’, developed by Oxford University and pharmaceutical company AstraZeneca and manufactured by Serum Institute of India at Pune, have been cleared by the DCGI for emergency use. Both the vaccines are in use during the nationwide immunisation programme launched on January 16.

The move to include Covaxin even before the publication of data from its phase 3 trial had come under criticism from some quarters. However, the regulator had defended the decision by saying that both the vaccines were totally safe.

Over 500 adverse reactions were reported from across the country during two days of immunisation. Two deaths were also reported but the government clarified that these were not related to vaccination.

Bharat Biotech said in case of any Serious Adverse Events (SAV), vaccine recipients will be provided medically recognised standards of care in government-designated and authorised centers/hospitals. Compensation for serious adverse event will be paid by Bharat Biotech International Limited and if SAV is proved to be casually related to the vaccine. The compensation amount will be determined by the ICMR Central Ethics Committee, it added.

 

IANS

 

Tags: allergiesBharat Biotechcoronavirus vaccineCovaxin
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Bijswajit Pradhan

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Ankita Balabantray

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Matrumangal Jena

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Adweeti Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Narendra Kumar

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019

Archives

Editorial

India’s Spy Shift

July 5, 2025

India’s espionage architecture is quietly shifting. The appointment of Parag Jain as the new chief of RAW comes at a...

Read more

Hungary Lessons

Hungary
July 2, 2025

Revolting against oppression and seeking freedom is ingrained in human nature, something that a repressive regime finds out sooner or...

Read more

New Democratic Face

Zohran Mamdani
July 1, 2025

US President Donald Trump, who had comfortably defeated his Democratic rival Kamala Harris in the recent presidential election and exuded...

Read more

Proof To Vote

Vote
June 30, 2025

Months ahead of the Assembly polls in Bihar, the Election Commission of India (ECI) on 28 June launched a ‘special...

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2024 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST